urovestВестник урологииUrology Herald2308-6424Rostov State Medical University10.21886/2308-6424-2017-5-2-42-49urovest-149Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS ARTICLEЛЕЧЕНИЕ НЕМЫШЕЧНО-ИНВАЗИВНОГО РАКА МОЧЕВОГО ПУЗЫРЯ ВЫСОКОГО РИСКАTREATMENT OF NON-MUSCLE-INVASIVE HIGH-RISK BLADDER CANCERhttps://orcid.org/0000-0003-3001-2451ИвановС. А.IvanovS. A.

доктор медицинских наук, заместитель директора по научной и лечебной работе МРНЦ им. А.Ф. Цыба - филиал ФГБУ «НМИРЦ» МЗ РФ; Обнинск

Obninsk

oncourog@gmail.comhttps://orcid.org/0000-0001-5988-8268ЗаборскийИ. Н.ZaborskiiI. N.

научный сотрудник отделения лучевого и хирургического лечения урологических заболеваний с группой брахитерапии рака предстательной железы МРНЦ им. А.Ф. Цыба - филиал ФГБУ «НМИРЦ» МЗ РФ; Обнинск

Obninsk

i.zaborskii@mail.ruhttps://orcid.org/0000-0002-8711-4937ЧайковВ. С.ChaikovV. S.

научный сотрудник отделения лучевого и хирургического лечения урологических заболеваний с группой брахитерапии рака предстательнойжелезы МРНЦ им. А.Ф. Цыба - филиал ФГБУ «НМИРЦ»; Обнинск

Obninsk

chaykovvv@mail.ruМедицинский радиологический научный центр им. А.Ф. Цыба ‒ филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» МЗ РФРоссияTsyb Medical Radiological Research Center - branch of the National Medical Researchadiological CenterRussian Federation201708072017524249Copyright © Иванов С.А., Заборский И.Н., Чайков В.С., 20172017Иванов С.А., Заборский И.Н., Чайков В.С.Ivanov S.A., Zaborskii I.N., Chaikov V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.urovest.ru/jour/article/view/149

В статье описаны современные методы диагностики и лечения немышечно-инвазивного рака мочевого пузыря. Возможности и перспективы современных методов диагностики и лечения. Приведен анализ зарубежной литературы.

The article describes modern methods of diagnosis and treatment of non-muscle-invasive bladder cancer. Possibilities and prospects of modern methods of diagnosis and treatment. The analysis of foreign literature is given.

немышечно-инвазивный рак мочевого пузыря высоко рискаиммунотерапия рака мочевого пузыряхимиотерапия рака мочевого пузыряхирургическое лечениеNon-muscle-invasive bladder cancerhigh riskimmunotherapy for bladder cancerchemotherapy for bladder cancersurgical treatmentReferencesСостояние онкологической помощи населению России в 2015 году. Под редакцией Каприна А.Д., Старинского В.В., Петровой Г.В. Москва; 2016.Caprin AD, Starinskу VV, Petrov GV, eds. The state of oncological assistance to the population of Russia in 2015. Moscow; 2016.Волкова М.И., Матвеев В.Б., Медведев С.В., Носов Д.А., Фигурин К.М., и др. Клинические рекомендации по диагностике и лечению больных раком мочевого пузыря. Москва; 2014.Volkova MI, Matveev VB, Medvedev SV, Nosov DA, Figurin KM, et al. Clinical recommendations for the diagnosis and treatment of patients with bladder cancer. Moscow; 2014.Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol. 2009;22(2):53-9. doi: 10.1038/modpathol.2008. p.193Tetu B. Diagnosis of urothelial carcinoma from urine. Mod Pathol. 2009;22(2):53-9. doi: 10.1038/modpathol.2008. p.193Сафиуллин К.Н. Лечение немышечно-инвазивного рака мочевого пузыря: Дис. …доктора медицинских наук. Обнинск; 2012.Safiullin KN. Treatment of non-muscle-invasive bladder cancer [dissertation]. Obninsk; 2012.Доступно по: http://medical-diss.com/medicina/ lechenie-nemyshechno-invazivnogo-raka-mochevogopuzyrya. Ссылка активна на 01.04.2017.Sanseverino R, Napodano G, Campitelli A, Addesso M. Prognostic impact of ReTURB in high grade T1 primary bladder cancer. Arch Ital Urol Androl. 2016;88(2):81-5. doi: 10.4081/aiua.2016.2.81Sanseverino R, Napodano G, Campitelli A, Addesso M. Prognostic impact of ReTURB in high grade T1 primary bladder cancer. Arch Ital Urol Androl. 2016;88(2):81-5. doi: 10.4081/aiua.2016.2.81Volkova MI, Matveev VB, Medvedev SV, Nosov DA, Figurin KM, et al. Clinical recommendations for the diagnosis and treatment of patients with bladder cancer. Moscow; 2014.Волкова М.И., Матвеев В.Б., Медведев С.В., Носов Д.А., Фигурин К.М., и др. Клинические рекомендации по диагностике и лечению больных раком мочевого пузыря. Москва; 2014.Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170: 433- 437. doi: 10.1097/01.ju.0000070437.14275.e0Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170: 433- 437. doi: 10.1097/01.ju.0000070437.14275.e0Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175(5):1641-1644. doi: 10.1016/s0022-5347(05)01002-5Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol. 2006;175(5):1641-1644. doi: 10.1016/s0022-5347(05)01002-5Raj GV, Herr H, Serio AM, Donat SM, Bochner BH et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007;177(4):1283-1286. doi: 10.1016/j.juro.2006.11.090Raj GV, Herr H, Serio AM, Donat SM, Bochner BH et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol. 2007;177(4):1283-1286. doi: 10.1016/j.juro.2006.11.090Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675. doi:10.1200/jco.2001.19.3.666Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666-675. doi:10.1200/jco.2001.19.3.666Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: longterm results in 1100 patients. Eur Urol. 2012;61(5):1039- 47. doi: 10.1016/j.eururo.2012.02.028Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: longterm results in 1100 patients. Eur Urol. 2012;61(5):1039- 47. doi: 10.1016/j.eururo.2012.02.028Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176:2414-2422. doi: 10.1016/j.juro.2006.08.004Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176:2414-2422. doi: 10.1016/j.juro.2006.08.004Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186-2190. doi: 10.1097/01.ju.0000125486.92260.b2Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171:2186-2190. doi: 10.1097/01.ju.0000125486.92260.b2Babjuk М, Burger М, Zigeuner R, Shariat SF, van Rhijn BWG et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–653. doi: 10.1016/j.eururo.2013.06.003Babjuk М, Burger М, Zigeuner R, Shariat SF, van Rhijn BWG et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–653. doi: 10.1016/j.eururo.2013.06.003Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195–2203. doi. 10.1016/j. juro.2009.07.016Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195–2203. doi. 10.1016/j. juro.2009.07.016Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non– muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol. 2015;68(2):256-62. doi: 10.1016/j.eururo.2015.02.040Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non– muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol. 2015;68(2):256-62. doi: 10.1016/j.eururo.2015.02.040Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JMF et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174:1242– 1247. doi: 10.1097/01.ju.0000173919.28835.aaMartinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JMF et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol. 2005;174:1242– 1247. doi: 10.1097/01.ju.0000173919.28835.aaBöhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90- 95. doi: 10.1097/00005392-200301000-00023Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169(1):90- 95. doi: 10.1097/00005392-200301000-00023Han RF, Pan JG. Can intravesical bacillus CalmetteGuérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216-1223. doi: doi.org/10.1016/j. urology.2005.12.014Han RF, Pan JG. Can intravesical bacillus CalmetteGuérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216-1223. doi: doi.org/10.1016/j. urology.2005.12.014Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209- 216. doi: 10.1046/j.1464-410x.2001.02306.xShelley MD, Kynaston H, Court J, Wilt TJ, Coles B et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209- 216. doi: 10.1046/j.1464-410x.2001.02306.xShelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485-490. doi:10.1111/j.1464- 410x.2003.04655.xShelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD. Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int. 2004;93(4):485-490. doi:10.1111/j.1464- 410x.2003.04655.xGontero P, Oderda M, Mehnert A, Gurioli A, Marson F et al. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190(3):857-862. doi: 10.1016/j. juro.2013.03.097Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F et al. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190(3):857-862. doi: 10.1016/j. juro.2013.03.097Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol. 2003;26(4):402-407. doi: 10.1097/01. coc.0000026911.98171.c6Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol. 2003;26(4):402-407. doi: 10.1097/01. coc.0000026911.98171.c6Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol. 2003;26(4):402-407. doi: 10.1097/01. coc.0000026911.98171.c6

The authors declare that there are no conflicts of interest present.